SKELAXIN
METAXALONE
Approval overview SKELAXIN is listed in Drugs@FDA under application 013217 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient METAXALONE Form and strength TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor KING PHARMS Submission history Latest submission status date: 2024-06-21 00:00:00.
Structured Monograph
Clinical summary
Approval overview SKELAXIN is listed in Drugs@FDA under application 013217 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient METAXALONE Form and strength TABLET;ORAL - 400MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor KING PHARMS Submission history Latest submission status date: 2024-06-21 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.